To improve the immune checkpoint blockade therapeutic efficacy via a genome-editing strategy, Ping’s group proposed a PTT-targeted PD-L1 genome-editing method through utilizing the supramolecular cationic AuNRs to reprogram the tumor immunosuppressive microenvironment for engendering efficient NIR-II PTT and immunotherapy [73]. The gene discussed is CD274; the disease is neoplasm.